Recently, I saw some fund sales advertisements claiming that 'medical insurance supports innovative drugs'. It is true that medical insurance should be willing to support innovative drugs, but willingness does not equate to ability. The core issue is

As we all know, China's healthcare insurance is divided into two parts. One is the employee healthcare insurance, which serves employed individuals and is jointly paid by the unit and individuals, covering 379 million people. At present, the premium

For the staff medical insurance, it seems to still have enough strength to support innovative drugs. But please note that the ratio of active working staff to retired personnel has decreased significantly. While active staff (and their companies) pay

The "resident medical insurance" may not have much ability to support innovative drugs, because it is already relying on huge financial subsidies. Otherwise, its expenditure is far greater than its income. The recent economic situation is not good, a

In summary, from the perspective of capability, even if the healthcare insurance industry makes significant efforts to support innovative drugs, the amount of money it can allocate is still very limited. Therefore, from an investment standpoint, we c